摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(8R,9S,10R,13S,14S,17S)-10,13-二甲基-6-亚甲基-3-氧代-2,7,8,9,11,12,14,15,16,17-十氢-1H-环戊并[a]菲-17-基]乙酸酯 | 1100-17-0

中文名称
[(8R,9S,10R,13S,14S,17S)-10,13-二甲基-6-亚甲基-3-氧代-2,7,8,9,11,12,14,15,16,17-十氢-1H-环戊并[a]菲-17-基]乙酸酯
中文别名
——
英文名称
17β-acetoxy-6-methylene-4-androsten-3-one
英文别名
17β-acetoxy-6-methylenandrost-4-en-3-one;6-Metilen-Δ4-androsten-17β-ol-3-one-17-acetato;17β-Acetoxy-3-oxo-6-methylen-testen-(4);6-Methylen-testosteron-acetat;6-Methylentestosteron-acetat;6-Methylenetestosterone acetate;[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-6-methylidene-3-oxo-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
[(8R,9S,10R,13S,14S,17S)-10,13-二甲基-6-亚甲基-3-氧代-2,7,8,9,11,12,14,15,16,17-十氢-1H-环戊并[a]菲-17-基]乙酸酯化学式
CAS
1100-17-0
化学式
C22H30O3
mdl
——
分子量
342.478
InChiKey
PNUPHAWFSSBOAI-RLZRBERESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    25
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:cb66525301830b777aad0b675a99785b
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Process for preparing 6-methylene steroids
    申请人:Schering Aktiengesellschaft
    公开号:US04322349A1
    公开(公告)日:1982-03-30
    A process for preparing a 6-methylene-.DELTA..sup.4 -3-keto steroid of the formula ##STR1## wherein R is hydrogen, alkoxy of up to 6 carbon atoms or acyloxy of up to 6 carbon atoms wherein the acyl group is that of a carboxylic acid, and R' is the CD-ring system of a steroid of the androstane or pregnane series, comprising reacting the corresponding .DELTA..sup.4 -3-keto steroid of the formula ##STR2## with a formaldehyde derivative of the formula X(CH.sub.2 O).sub.n Y wherein n is 1, 3 or an integer on the order of 100-1000, and X is C.sub.1-5 alkoxy and Y is C.sub.1-5 alkyl when n is 1, X and Y represent a single bond between the terminal C atom and the terminal O atom when n is 3, and X is hydroxy and Y is hydrogen when n is an integer on the order of 100-1000, in an inert solvent in the presence of a condensation agent which is a strong acid a strongly acidic cation exchanger or a phosphoric acid derivative.
    一种制备式的6-亚甲基-Δ4-3-酮类固醇的方法,其中R为氢、最多含有6个碳原子的烷氧基或最多含有6个碳原子的乙酰氧基,其中酰基是羧酸的酰基,R'为雄甾烷或孕烷系列类固醇CD环系统,包括将相应的Δ4-3-酮类固醇与式的甲醛生物反应X(CH2O)nY,其中n为1、3或约为100-1000的整数,X为C1-5烷氧基,Y为C1-5烷基,当n为1时,X和Y代表末端C原子和末端O原子之间的单键,当n为3时,X和Y代表末端C原子和末端O原子之间的单键,当n为约为100-1000的整数时,X为羟基,Y为氢,在惰性溶剂中,在存在强酸、强酸性阳离子交换剂或磷酸生物的缩聚剂的情况下进行。
  • COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
    申请人:Johansen Lisa M.
    公开号:US20100009970A1
    公开(公告)日:2010-01-14
    The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
    本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中,病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中,病毒性疾病是病毒性肝炎(例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎),药剂或药剂组合包括舍曲林舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
  • Process for obtaining 6-Alkylidenandrost-1,4-diene-3one
    申请人:Crystal Pharma, S.A.
    公开号:EP2070943A1
    公开(公告)日:2009-06-17
    6-alkylidenandrost-1,4-dien-3-ones of general formula (I), wherein R is H o alkyl; R1 y R2, independently of one another, represent H, OR3, OC(=O) R4 or O-(GPH), wherein R3 is H; C1-C6 alkyl or aryl; R4 is H or C1-C6 alkyl,; and GPH is a hydroxyl protecting group; or R1 and R2, together with the carbon atom to which they are bonded, form a carbonyl group or equivalent or a cyclic ketal; can be obtained by a process comprising subjecting the corresponding 6-alkyliden-4-androsten-3-one to a dehydrogenation reaction in the 1,2 position in the presence of a quinine, a silylating agent and a strong acid.
    通式为(I)的6-烷基亚甲基睾酮-1,4-二烯-3-酮,其中R为H或烷基;R1和R2独立地表示H、OR3、OC(=O)R4或O-(GPH),其中R3为H、C1-C6烷基或芳基;R4为H或C1-C6烷基;GPH为羟基保护基;或R1和R2与它们所连接的碳原子一起形成一个羰基团或等效的环糊精;可以通过在奎宁化剂和强酸存在下,将相应的6-烷基亚甲基-4-雄烯-3-酮进行1,2位置的脱氢反应而获得。
  • On the optical activity of α,β-unsaturated ketones
    作者:H. Ziffer、C.H. Robinson
    DOI:10.1016/s0040-4020(01)96311-2
    日期:1968.1
    The ORD curves of several α,β-unsaturated ketones are compared with those of structurally related dienes and the similarities and differences discussed. A determination of the CD curves of a number of α,β-unsaturated ketones revealed the presence of a new very strong optically active transition close to that of the π → π* transition. The sign of the Cotton effect associated with the π → π* transition
    比较了几种α,β-不饱和酮的ORD曲线与结构相关二烯的ORD曲线,并讨论了它们的异同。对许多α,β-不饱和酮的CD曲线的测定揭示了存在一个新的非常强的光学活性跃迁,该跃迁接近于π→π *跃迁。由ORD测量确定的与π→π *跃迁相关的Cotton效应的符号有时会因重叠的新跃迁而被遮盖。在研究环大小对这些跃迁的旋光性的符号和强度的影响时,确定了许多α,β-不饱和酮的CD曲线。
  • PROCESS FOR OBTAINING 6-ALKYLIDENANDROST-1, 4-DIENE-3-ONE
    申请人:Bermejo González Francisco
    公开号:US20110118488A1
    公开(公告)日:2011-05-19
    6-alkylidenandrost-1,4-dien-3-ones of general formula (I), wherein R is H o alkyl; R 1 y R 2 , independently of one another, represent H, OR 3 , OC(═O)R 4 or O-(GPH), wherein R 3 is H; C 1 -C 6 alkyl or aryl; R 4 is H or C 1 -C 6 alkyl, and GPH is a hydroxyl protecting group; or R 1 and R 2 , together with the carbon atom to which they are bonded, form a carbonyl group or equivalent or a cyclic ketal; can be obtained by a process comprising subjecting the corresponding 6-alkyliden-4-androsten-3-one to a dehydrogenation reaction in the 1,2 position in the presence of a quinone, a silylating agent and a strong acid.
    通式为(I)的6-烷基烯基雄烯-1,4-二烯-3-酮,其中R为氢或烷基;R1和R2独立地代表氢、OR3、OC(═O)R4或O-(GPH),其中R3为氢、C1-C6烷基或芳基;R4为氢或C1-C6烷基,GPH是羟基保护基;或R1和R2与它们所连接的碳原子一起形成一个羰基或等效的环糊精;可通过在醌、基化剂和强酸存在下,使相应的6-烷基烯基-4-雄烯-3-酮在1,2位进行脱氢反应而获得。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B